Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2023 Net Income-$4.72M-$4.72MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$5,548,000N/M Operating Cash Flowderived-$3,293,000N/M Free Cash Flowderived-$3,293,000N/M ended Jun 30, 2024 · filed Sep 26, 2024 · 88 d after period end